At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 580 enrolled
Drug / intervention
Galcanezumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
In Brief
A Phase 4 clinical trial evaluating Galcanezumab, Rimegepant, and 1 other intervention for Migraine and Episodic Migraine. Completed, enrolled 580 participants across 77 sites.
Detailed Summary
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Episodic Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartDec 2021
Primary CompletionMay 2023
TodayJul 2026
First PostedNov 19, 2021
Enrollment StartDec 6, 2021
Primary CompletionMay 23, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.6 years ago
Interventions
Galcanezumabdrug
Administered SC.
Rimegepantdrug
Administered orally.
Placebodrug
Administered orally.
Placebodrug
Administered SC.